Amgevita Biosimilars and Biologic Medicines | About Us | Amgen

You are leaving Amgevita.EU website and entering another Amgen website

You are leaving Amgevita.EU website and entering another Amgen website

You are now leaving Amgevita.EU
Amgen does not endorse or accept liability for sites controlled by third parties

Return to previous page Continue

Countries ▼

AMGEN'S NEARLY FOUR
DECADES OF EXPERIENCE

Amgen is an expert in the development of biologic medicines

Since 1980, Amgen has been at the forefront of biotechnology, helping invent the processes and tools that built the global biotechnology industry into the leading source of therapies for patients with few other options. Our expertise in biologics is now being applied into developing high quality, therapeutic biosimilars in order to deliver more value to both patients and healthcare systems.
Image showing the key benefits of Amgen's biosimilars.
Amgen biosimilars
Read more
  1. Tabernero J, et al. ESMO Open. 2016;1:e000142.
  2. World Health Organization. 11th General Programme of Work Executive Summary. Available at: www.who.int/about/vision/global_health_agenda/en/. Last accessed March 2019.
  3. Colombel JF, et al. Gastroenterology. 2017;152:351–61.

Home

SmPC

footerbg

AMGEVITA® is authorised for the following indications by the European Commission:
AMGEVITA® is an adalimumab biosimilar indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, uveitis and paediatric uveitis.
> See full indication
AMGEVITA® (adalimumab) Summary of Product Characteristics. Available at: www.ema.europa.eu. Last revised March 2020.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >
I am not an EU healthcare professional
Read more >
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.